Clonality of Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 550
- 主要终点
- Overall survival
研究概览
简要总结
Molecular alterations in Homologous Recombination Repair (HRR) genes have been associated with clinical benefit from chemotherapy and/or Poly (ADP-ribose) polymerase (PARP) inhibitors in patients with epithelial ovarian cancer. Therefore, the performance of tumor molecular profiling is currently recommended by international guidelines at initial diagnosis, among other reasons, for the modification of the treatment plan. The investigators' hypothesis was that tumor molecular profiling reveals additional parameters that can improve the predictive and prognostic role of the mere presence of HRR gene mutations. The study aimed to investigate the prognostic and predictive role of clonality of pathogenic variants in HRR genes and/or concurrent pathogenic variants in other clinically relevant genes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with epithelial ovarian cancer
- •Received treatment at HeCOG-affiliated institutions
- •Have signed informed consent
- •With adequate tumor tissue for analysis
排除标准
- 未提供
结局指标
主要结局
Overall survival
时间窗: Through study completion, an average of 3 years
The time from ovarian cancer diagnosis to the date of death from any cause
次要结局
- Progression-free survival(From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 96 months)